Advanced Search

 

Study ID Status Title Patient Level Data
SAS10020 Completed A single dose, randomized, double-blind, 2-way crossover study to assess the safety, tolerability, pharmacodynamics and pharmacokinetic profile of SERETIDE™ 50/50 compared to concurrent administration of individual FP 50 and SALM 50 inhalers in healthy subjects aged 18 – 55 years. Study Listed on ClinicalStudyDataRequest.com
SAS104449 Completed A randomised, open label, five-way crossover study to assess the systemic exposure of fluticasone propionate and salmeterol from SERETIDE/ADVAIR 250HFA MDI alone and with AeroChamber-Max spacer and VOLUMATIC both in their washed and unwashed states in adult subjects with mild or intermittent asthma Study Listed on ClinicalStudyDataRequest.com
SAS105519 Completed A repeat-dose, open-label, randomized, incomplete block design in pediatric subjects with asthma, ages 4 - 11 years, to compare systemic exposure and pharmacodynamics of fluticasone propionate and salmeterol following Advair HFA 45/21mcg (2 inhalations), ADVAIR® HFA 45/21mcg (2 inhalations) with Aerochamber Plus Spacer and Advair Diskus 100/50 twice daily Study Listed on ClinicalStudyDataRequest.com
SAS107541 Completed A long term follow up study for a comparison of stepwise treatment of asthmatic children with Salmeterol/Fluticasone propionate combination product (SERETIDE®) and/or Fluticasone propionate (FLIXOTIDE (TM)) based on PD20 methacholine and symptoms or based on symptoms only.
SAS20008 Completed A 12 week open study to assess the efficacy and safety of Seretide Diskus 50/250mcg, 1 inhalation twice daily in patients with reversible airway obstruction compatible with the diagnosis of asthma.
SAS30001 Completed A Randomized, Double-Blind, Active-Controlled, Parallel-Group, 12-Week Trial Evaluating the Safety and Efficacy of the Salmeterol/Fluticasone Propionate Combination in HFA 134a MDI, 42/88mcg BID, and Salmeterol in Propellant 11/12 MDI, 42mcg BID, and Fluticasone Propionate in Propellant 11/12 MD ...
SAS30003 Completed A Stratified, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week Trial Evaluating the Safety and Efficacy of the Salmeterol/Fluticasone Propionate Combination in HFA 134a MDI, 42/88mcg BID, and Salmeterol in Propellant 11/12 MDI, 42mcg BID, Fluticasone Propionate in Propellant ...
SAS30004 Completed A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group 12-Week Trial Evaluating the Safety and Efficacy of the Salmeterol/Fluticasone Propionate Combination...
SAS30005 Completed A 12-Month, Open-Label, Stratified Study to Assess the Long-Term Safety of Salmeterol/Fluticasone Propionate/HFA134a Inhalation Aerosol at Doses of 50/100mcg, 50/250mcg, and 50/500mcg BID in Adolescent and Adult Subjects with Asthma
SAS30013 Completed A study to compare the long term effects on airway inflammation of Seretide versus Flixotide in adult subjects with asthma.
SAS30014 Completed A single-centre, double-blind, randomised, cross-over study to compare the short term effects on airway inflammation after allergen challenge of salmeterol/fluticasone propionate combination product (Seretide) versus fluticasone propionate (Flixotide) in adult subjects with asthma.
SAS30015 Completed A phase IIIB, multi-centre, double-blind, parallel group, randomised study to compare the efficacy of the salmeterol/fluticasone propionate combination (25/50 mcg strength), 2 inhalations bd via HFA-MDI with beclomethasone dipropionate (BDP) 200mcg bd via metered...
SAS30017 Completed A Randomized, Double-Blind, Active-Controlled, Parallel-Group 12-Week Trial Evaluating the Safety and Efficacy of the 50/100mcg Salmeterol/Fluticasone Propionate DISKUS Combination Product twice daily Compared with Salmeterol 50mcg via DISKUS twice daily and Fluticasone Propionate 100mcg via DISKUS twice daily in Adult and Adolescent Subjects with Asthma on Short-Acting Beta2-Agonist Therapy Study Listed on ClinicalStudyDataRequest.com
SAS30018 Completed Comparison of stepwise treatment of asthmatic children with Salmeterol/Fluticasone propionate combination product (Seretide®) and/or Fluticasone propionate (Flixotide®) based on PD20 methacholine and symptoms or based on symptoms only (Children Asthma Therapy Optimal)
SAS30019 Completed A multicentre, randomised, double-blind, double-dummy, parallel group study to compare salmeterol/fluticasone propionate combination 50/100mcg twice daily delivered via dry powder inhaler (Diskus/Accuhaler) or non-chlorofluorocarbon metered-dose inhaler in the treatment of children with asthma aged 4-11 years. Study Listed on ClinicalStudyDataRequest.com
SAS30021 Completed A stratified, randomized, double-blind, placebo-controlled, parallel-group, 12 week trial evaluating the safety and efficacy of fluticasone propionate/salmeterol DISKUS combination product 100/50mcg once daily versus fluticasone propionate DISKUS 100mcg once daily and placebo in symptomatic pediatric subjects (4-11 years) with asthma Study Listed on ClinicalStudyDataRequest.com
SAS30022 Completed A randomized, double-blind, placebo-controlled, parallel-group, 12 week trial evaluating the safety and efficacy of the fluticasone propionate/salmeterol DISKUS combination product 250/50mcg once daily versus fluticasone propionate 250mcg once daily versus fluticasone propionate/salmeterol 100/50mcg twice daily versus placebo in symptomatic adolescent and adult subjects with asthma that is not controlled on short acting beta agonist therapy Study Listed on ClinicalStudyDataRequest.com
SAS30023 Completed A 12-week multicentre, randomised, double-blind, placebo-controlled parallel group study to compare the efficacy and tolerability of fluticasone propionate/salmeterol combination (SERETIDE/VIANI/ADVAIR) 88/42mcg once daily in the morning with fluticasone propionate 88mcg once daily in the morning and placebo (short-acting ß2-agonist as required only) once daily in the morning, all via the HFA MDI as initial maintenance therapy in mild asthmatic subjects Study Listed on ClinicalStudyDataRequest.com
SAS30024 Completed A 52-week multicentre, randomised, double-blind, double dummy, placebo-controlled parallel group study to compare the efficacy and tolerability of salmeterol/fluticasone propionate combination (SERETIDE/VIANI/ADVAIR) 50/100mcg once daily in the morning with fluticasone propionate (FLIXOTIDE/FLOV ... Study Listed on ClinicalStudyDataRequest.com
SAS30025 Completed Seretide for COntrol of REspiratory symptoms (SCORE): Switching inhaled steroids to Seretide in persistent asthma in general practice. An open label, sequential trial.
SAS30031 Completed A Randomized, Double-Blind, 12-Week Trial Evaluating the Safety of the Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50mcg twice daily Versus Fluticasone Propionate DISKUS 100mcg twice daily in Symptomatic Pediatric Subjects (4-11 Years) With Asthma Study Listed on ClinicalStudyDataRequest.com
SAS30033 Completed An Open-Label, Multi-Center Study to Evaluate the Performance and Patient Satisfaction of Fluticasone Propionate/Salmeterol HFA with Counter in Asthma or COPD Subjects at Least 12 Years of Age Study Listed on ClinicalStudyDataRequest.com
SAS30035 Completed A 52-week multi-centre, open-labelled, non-comparative study assessing the safety of salmeterol xinafoate/fluticasone propionate bid in adult patients with bronchial asthma
SAS30036 Completed A Double-Blind, Comparative Study to Compare Salmeterol/Fluticasone Propionate Combination Product (50/250mcg BID) with Concomitant Treatment with Fluticasone Propionate 250mcg BID Plus Sustained ReleaseTheophylline 200mg bid in Patients with Bronchial Asthma
SAS30038 Completed Clinical assessment of GW815SF (SLM/FP) for bronchial asthma - An open-labelled study of GW815SF (SLM/FP) 50/100mcg in patients with bronchial asthma (uncontrolled trial).

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.